COVID-19 Outbreak Information –

Peter Wilden

Chairman of the Board of Directors of PolyPeptide Group

Peter Wilden, Chairman of the Board of Directors of PolyPeptide Group, is a German citizen born in 1957. Between 2000 and 2017, Mr. Wilden was Executive Vice President and CFO of Ferring Pharmaceuticals. Currently, Mr. Wilden is Executive Chairman of Ferring International Center SA, Saint-Prex (since 2002). He also serves as Vice Chairman of Schlumberger AG, Austria (since 2014), Member of the Board of Directors of Ferring Ventures SA, Lausanne (since 2014), Vice Chairman of Project HOPE in the U.S. (since 2012) and Chairman of Project HOPE Suisse International Foundation (since 2015). Between 2004 and 2014, Mr. Wilden was a member of the Board of Directors and Chairman of the Audit Committee of Lonza Group AG, Basel. Mr. Wilden holds a PhD in Economics and an MBA in Industrial Economics, both from the University of Kiel, Germany.